Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model

Alzheimer's Research and Therapy

Volumn 5, Issue 6, 2013, Pages

  Meister, Sabrina ^a   Zlatev, Iavor ^b   Stab, Julia ^c   Docter, Dominic ^a   Baches, Sandra ^d   Stauber, Roland H ^a   Deutsch, Mordechai ^e   Schmidt, Reinhold ^f   Ropele, Stefan ^f   Windisch, Manfred ^g   Langer, Klaus ^b   Wagner, Sylvia ^c   Von Briesen, Hagen ^c   Weggen, Sascha ^d   Pietrzik, Claus U ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c FRAUNHOFER INSTITUTE FOR BIOMEDICAL ENGINEERING   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e BAR ILAN UNIVERSITY   (Israel)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g NeuroScios GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; FLURBIPROFEN; GAMMA SECRETASE; NANOPARTICLE; POLYLACTIDE;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOTOXICITY; DIFFUSION; DRUG TRANSPORT; EMULSION; ENDOCYTOSIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; MODULATION; MOUSE; NANOEMULSION; NONHUMAN; PLASMA; PRIORITY JOURNAL;

EID: 84889058853     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt225     Document Type: Article

References (52)

1. Alzheimer's disease. HW Querfurth, FM LaFerla, N Engl J Med 2010 362 329 344 10.1056/NEJMra0909142 20107219
2. Alzheimer's disease facts and figures. Alzheimer's Association, Alzheimers Dement 2012 2012 131 168
3. Alzheimer's disease: Abeta, tau and synaptic dysfunction. FM LaFerla, S Oddo, Trends Mol Med 2005 11 170 176 10.1016/j.molmed.2005.02.009 15823755
4. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. C Haass, DJ Selkoe, Cell 1993 75 1039 1042 10.1016/0092-8674(93)90312-E 8261505
5. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. D Burdick, B Soreghan, M Kwon, J Kosmoski, M Knauer, A Henschen, J Yates, C Cotman, C Glabe, J Biol Chem 1992 267 546 554 1730616
6. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. YM Kuo, MR Emmerling, C Vigo-Pelfrey, TC Kasunic, JB Kirkpatrick, GH Murdoch, MJ Ball, AE Roher, J Biol Chem 1996 271 4077 4081 10.1074/jbc.271.8.4077 8626743
7. Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. T Jefferson, M Causevic, U auf dem Keller, O Schilling, S Isbert, R Geyer, W Maier, S Tschickardt, T Jumpertz, S Weggen, JS Bond, CM Overall, CU Pietrzik, C Becker-Pauly, J Biol Chem 2011 286 27741 27750 10.1074/jbc.M111.252718 21646356
8. The metalloprotease meprin beta generates amino terminal-truncated amyloid beta peptide species. J Bien, T Jefferson, M Causevic, T Jumpertz, L Munter, G Multhaup, S Weggen, C Becker-Pauly, CU Pietrzik, J Biol Chem 2012 287 33304 33313 10.1074/jbc.M112.395608 22879596
9. The molecular pathology of Alzheimer's disease. DJ Selkoe, Neuron 1991 6 487 498 10.1016/0896-6273(91)90052-2 1673054
10. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. J Hardy, D Allsop, Trends Pharmacol Sci 1991 12 383 388 1763432
11. Alzheimer's disease: the amyloid cascade hypothesis. JA Hardy, GA Higgins, Science 1992 256 184 185 10.1126/science.1566067 1566067
12. Alzheimer disease therapy: can the amyloid cascade be halted? TE Golde, J Clin Invest 2003 111 11 18 12511580 (Pubitemid 36134840)
13. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? T Wyss-Coray, Nat Med 2006 12 1005 1015 16960575 (Pubitemid 44353380)
14. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. E McGowan, F Pickford, J Kim, L Onstead, J Eriksen, C Yu, L Skipper, MP Murphy, J Beard, P Das, K Jansen, M Delucia, WL Lin, G Dolios, R Wang, CB Eckman, DW Dickson, M Hutton, J Hardy, T Golde, Neuron 2005 47 191 199 10.1016/j.neuron.2005.06.030 16039562 (Pubitemid 41019251)
15. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. JK Sahni, S Doggui, J Ali, S Baboota, L Dao, C Ramassamy, J Control Release 2011 152 208 231 10.1016/j.jconrel.2010.11.033 21134407
16. The many substrates of presenilin/gamma-secretase. A Haapasalo, DM Kovacs, J Alzheimers Dis 2011 25 3 28 21335653
17. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. S Weggen, JL Eriksen, P Das, SA Sagi, R Wang, CU Pietrzik, KA Findlay, TE Smith, MP Murphy, T Bulter, DE Kang, N Marquez-Sterling, TE Golde, EH Koo, Nature 2001 414 212 216 10.1038/35102591 11700559 (Pubitemid 33051236)
18. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. TD Warner, JA Mitchell, FASEB J 2004 18 790 804 10.1096/fj.03-0645rev 15117884 (Pubitemid 38544498)
19. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. JL Eriksen, SA Sagi, TE Smith, S Weggen, P Das, DC McLendon, VV Ozols, KW Jessing, KH Zavitz, EH Koo, TE Golde, J Clin Invest 2003 112 440 449 12897211 (Pubitemid 38063773)
20. Chemical biology, molecular mechanism and clinical perspective of gamma-secretase modulators in Alzheimer's disease. B Bulic, J Ness, S Hahn, A Rennhack, T Jumpertz, S Weggen, Curr Neuropharmacol 2011 9 598 622 10.2174/157015911798376352 22798753
21. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. RC Green, LS Schneider, DA Amato, AP Beelen, G Wilcock, EA Swabb, KH Zavitz, Tarenflurbil Phase 3 Study Group, JAMA 2009 302 2557 2564 10.1001/jama.2009.1866 20009055
22. Delivery of imaging agents into brain. NJ Abbott, DC Chugani, G Zaharchuk, BR Rosen, EH Lo, Adv Drug Deliv Rev 1999 37 253 277 10.1016/S0169-409X(98)00097-0 10837739 (Pubitemid 29164512)
23. Astrocyte-endothelial interactions at the blood-brain barrier. NJ Abbott, L Ronnback, E Hansson, Nat Rev Neurosci 2006 7 41 53 10.1038/nrn1824 16371949 (Pubitemid 41828930)
24. Tight junction dynamics: is paracellular transport regulated? JL Madara, Cell 1988 53 497 498 3286009
25. Nanoparticulate systems for drug delivery and targeting to the central nervous system. EF Craparo, ML Bondi, G Pitarresi, G Cavallaro, CNS Neurosci Ther 2011 17 670 677 10.1111/j.1755-5949.2010.00199.x 20950327
26. Osmotic opening of tight junctions in cerebral endothelium. MW Brightman, M Hori, SI Rapoport, TS Reese, E Westergaard, J Comp Neurol 1973 152 317 325 10.1002/cne.901520402 4784295
27. Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. SI Rapoport, PJ Robinson, Ann N Y Acad Sci 1986 481 250 267 10.1111/j.1749-6632.1986.tb27155.x 3468860 (Pubitemid 17023278)
28. Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system. GA Silva, Ann N Y Acad Sci 2010 1199 221 230 10.1111/j.1749-6632.2009.05361.x 20633128
29. Polymeric nanoparticles for the drug delivery to the central nervous system. G Tosi, L Costantino, B Ruozi, F Forni, MA Vandelli, Expert Opin Drug Deliv 2008 5 155 174 10.1517/17425247.5.2.155 18248316 (Pubitemid 351308309)
30. Automated multi-well device to measure transepithelial electrical resistances under physiological conditions. J Wegener, D Abrams, W Willenbrink, HJ Galla, A Janshoff, Biotechniques 2004 37 590 592-594, 596-597 15517971
31. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. EH Koo, SL Squazzo, J Biol Chem 1994 269 17386 17389 8021238 (Pubitemid 24218009)
32. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure. S Hahn, T Bruning, J Ness, E Czirr, S Baches, H Gijsen, C Korth, CU Pietrzik, B Bulic, S Weggen, J Neurochem 2011 116 385 395 10.1111/j.1471-4159.2010.07118.x 21091478
33. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. S Grosch, I Tegeder, K Schilling, TJ Maier, E Niederberger, G Geisslinger, FASEB J 2003 17 1316 1318 12759338
34. Biomolecular coronas provide the biological identity of nanosized materials. MP Monopoli, C Aberg, A Salvati, KA Dawson, Nat Nanotechnol 2012 7 779 786 10.1038/nnano.2012.207 23212421
35. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Kreuter, D Shamenkov, V Petrov, P Ramge, K Cychutek, C Koch-Brandt, R Alyautdin, J Drug Target 2002 10 317 325 10.1080/ 10611860290031877 12164380 (Pubitemid 34746313)
36. Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. S Wagner, J Kufleitner, A Zensi, M Dadparvar, S Wien, J Bungert, T Vogel, F Worek, J Kreuter, H von Briesen, PLoS One 2010 5 14213 10.1371/journal.pone. 0014213 21151975
37. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. S Wagner, A Zensi, SL Wien, SE Tschickardt, W Maier, T Vogel, F Worek, CU Pietrzik, J Kreuter, H von Briesen, PLoS One 2012 7 32568 10.1371/journal.pone.0032568 22396775
38. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. A Zensi, D Begley, C Pontikis, C Legros, L Mihoreanu, S Wagner, C Buchel, H von Briesen, J Kreuter, J Control Release 2009 137 78 86 10.1016/j.jconrel.2009.03.002 19285109
39. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. T Pflanzner, MC Janko, B Andre-Dohmen, S Reuss, S Weggen, AJ Roebroek, CR Kuhlmann, CU Pietrzik, Neurobiol Aging 2011 32 2323 e1-11 20674093
40. Alzheimer's disease: genes, proteins, and therapy. DJ Selkoe, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
41. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Hardy, J Neurochem 2009 110 1129 1134 10.1111/j.1471-4159.2009.06181.x 19457065
42. Blood-brain barrier delivery. WM Pardridge, Drug Discov Today 2007 12 54 61 10.1016/j.drudis.2006.10.013 17198973 (Pubitemid 46014479)
43. Nanotechnology for neurodegenerative disorders. F Re, M Gregori, M Masserini, Nanomedicine 2012 8 51 S58 22640910
44. Biodegradable polymeric nanoparticles based drug delivery systems. A Kumari, SK Yadav, SC Yadav, Colloids Surf B: Biointerfaces 2010 75 1 18 10.1016/j.colsurfb.2009.09.001 19782542
45. Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. S Li, J Biomed Mater Res 1999 48 342 353 10.1002/(SICI)1097-4636(1999)48:3<342::AID-JBM20>3.0.CO;2-7 10398040 (Pubitemid 29242707)
46. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. DR Galasko, N Graff-Radford, S May, S Hendrix, BA Cottrell, SA Sagi, G Mather, M Laughlin, KH Zavitz, E Swabb, TE Golde, MP Murphy, EH Koo, Alzheimer Dis Assoc Disord 2007 21 292 299 10.1097/WAD.0b013e31815d1048 18090435 (Pubitemid 350307433)
47. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. S Wagner, F Rothweiler, MG Anhorn, D Sauer, I Riemann, EC Weiss, A Katsen-Globa, M Michaelis, J Cinatl Jr, D Schwartz, J Kreuter, H von Briesen, K Langer, Biomaterials 2010 31 2388 2398 10.1016/j.biomaterials.2009.11.093 20031203
48. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. C Roney, P Kulkarni, V Arora, P Antich, F Bonte, A Wu, NN Mallikarjuana, S Manohar, HF Liang, AR Kulkarni, HW Sung, M Sairam, TM Aminabhavi, J Control Release 2005 108 193 214 10.1016/j.jconrel.2005.07.024 16246446 (Pubitemid 41608654)
49. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. D Brambilla, B Le Droumaguet, J Nicolas, SH Hashemi, LP Wu, SM Moghimi, P Couvreur, K Andrieux, Nanomedicine 2011 7 521 540 10.1016/j.nano.2011.03.008 21477665
50. Therapeutic compliance of nanomedicine in Alzheimer's disease. B Wilson, Nanomedicine (Lond) 2011 6 1137 1139 10.2217/nnm.11.114
51. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. LY Rizzo, B Theek, G Storm, F Kiessling, T Lammers, Curr Opin Biotechnol 2013 doi: 10.1016/j.copbio.2013.02.020
52. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. K Michaelis, MM Hoffmann, S Dreis, E Herbert, RN Alyautdin, M Michaelis, J Kreuter, K Langer, J Pharmacol Exp Ther 2006 317 1246 1253 10.1124/jpet.105.097139 16554356 (Pubitemid 43764130)